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Summary
Background The persistence and effectiveness of systemic therapies for moderate-
to-severe psoriasis in current clinical practice are poorly characterized.
Objectives To systematically review observational studies investigating the persis-
tence and effectiveness of acitretin, ciclosporin, fumaric acid esters (FAE) and
methotrexate, involving at least 100 adult patients with moderate-to-severe psori-
asis, exposed to therapy for ≥ 3 months.
Methods MEDLINE, Embase, the Cochrane Library and PubMed were searched
from 1 January 2007 to 1 November 2017 for observational studies reporting on
persistence (therapy duration or the proportion of patients discontinuing therapy
during follow-up) or effectiveness [improvements in Psoriasis Area and Severity
Index (PASI) or Physician’s Global Assessment (PGA)]. This review was registered
with PROSPERO, number CRD42018099771.
Results Of 411 identified studies, eight involving 4624 patients with psoriasis
were included. Variations in the definitions and analyses of persistence and effec-
tiveness outcomes prevented a meta-analysis from being conducted. One prospec-
tive multicentre study reported drug survival probabilities of 23% (ciclosporin),
42% (acitretin) and 50% (methotrexate) at 1 year. Effectiveness outcomes were
not reported for either acitretin or ciclosporin. The persistence and effectiveness
of FAE and methotrexate were better characterized, but mean discontinuation
times ranged from 28 to 50 months for FAE and 77 to 223 months for
methotrexate. At 12 months of follow-up, three studies reported that 76% (FAE),
53% (methotrexate) and 59% (methotrexate) of patients achieved ≥ 75% reduc-
tion in PASI, and one reported that 76% of FAE-exposed patients achieved a
markedly improved or clear PGA.
Conclusions The comparative persistence and effectiveness of acitretin, ciclosporin,
FAE and methotrexate in real-world clinical practice in the past decade cannot be
well described due to the inconsistency of the methods used.
What’s already known about this topic?
• Research examining acitretin, ciclosporin, fumaric acid esters (FAE) and methotrex-
ate for the treatment of moderate-to-severe psoriasis has focused on safety and effi-
cacy in randomized controlled trials.
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• The persistence and effectiveness of acitretin, ciclosporin, FAE and methotrexate
since the introduction of biologic therapies in real-world clinical practice are
poorly understood.
What does this study add?
• This systematic review examines the persistence and effectiveness of methotrexate,
acitretin, ciclosporin and FAE for moderate-to-severe psoriasis.
• Data on the persistence and effectiveness of systemic therapies are lacking, particu-
larly for acitretin and ciclosporin.
• The definitions of persistence and reporting of effectiveness are inconsistent.
• Further good-quality observational studies are needed to explore the
real-world persistence and effectiveness of systemic treatments used for
psoriasis.
Psoriasis is a chronic inflammatory skin disorder that impairs
both physical and psychological health.1 Treatment options for
patients with psoriasis depend on disease severity, comorbid-
ities and patient choice and include topical, phototherapy and
systemic therapies (including biologics and small mole-
cules).2,3 More severe psoriasis frequently requires lifelong
management, and therefore counselling patients on the likeli-
hood of medium-to-long-term disease control is important
when discussing treatment choice.
In the U.K., guidance provided by the National Institute for
Health and Care Excellence (NICE) suggests the use of nonbio-
logic, nonsmall-molecule systemic therapies for the treatment
of moderate-to-severe psoriasis that cannot be controlled with
topical or phototherapies.3 Methotrexate is recommended as
first-line therapy, with ciclosporin advised in the short term
and for women considering conception. Acitretin may be con-
sidered if methotrexate and ciclosporin are contraindicated or
ineffective.3
Most of the available evidence related to systemic thera-
pies is derived from randomized controlled trials (RCTs).
These remain the gold standard for investigating new thera-
pies, as participant randomization to receive active or com-
parator treatments and high internal validity facilitate causal
inference of the efficacy and/or safety of the therapy under
investigation between the trial arms. However, most RCTs
are not fully representative of real-world clinical practice
and are powered for efficacy outcomes rather than safety.
Due to their relatively small sample sizes, short follow-up
periods and strict inclusion criteria, RCTs may have low
external validity.
Two studies have demonstrated that patients with psoria-
sis identified as ineligible for biologics RCTs are at least
twice as likely as eligible patients to experience serious
adverse events.4,5 Attrition with longer-term RCTs or open-
label extension studies may render the interpretation of
safety data difficult due to the resulting bias in the sample
studied. Postmarketing observational research is
complementary to prelicensing trials to enable the explo-
ration of the persistence (duration of time from initiating
to discontinuing therapy)6 and effectiveness (response to
therapy observed within real-world conditions accounting
for factors that may influence the therapy’s performance)7
of psoriasis therapies in clinical practice. Discontinuation of
systemic therapy is common in clinical practice, hence
long-term data collection is critical to investigating thera-
peutic outcomes.8,9 The British Association of Dermatologists
Biologics and Immunomodulators Register (BADBIR) is a
well-established prospective pharmacovigilance register of
patients diagnosed with psoriasis and treated with all forms
of systemic therapy.10 Observational data collected by regis-
ters such as BADBIR will provide important evidence for
the persistence and effectiveness of systemic psoriasis thera-
pies in real-world clinical practice.
We conducted a systematic review of the persistence and
effectiveness of four commonly used nonbiologic, nonsmall-
molecule systemic psoriasis therapies in observational studies
over the past decade. The aim was to summarize and evaluate
observational studies (involving ≥ 100 patients) investigating
the persistence and/or effectiveness of acitretin, ciclosporin,
fumaric acid esters (FAE) or methotrexate in adult patients
with moderate-to-severe psoriasis.
Materials and methods
Literature search
A literature search was completed utilizing Embase, MEDLINE,
PubMed and the Cochrane Library. Searches were limited to
humans and publications dated from 1 January 2007 to 1
November 2017 to account for research published within the
past decade, as the introduction of biologic therapies has
influenced systemic treatment prescribing. The full search
strategy and complete study protocol are listed in Appendix S1
(see Supporting Information).
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Inclusion criteria
Longitudinal observational studies were eligible for review,
including retrospective and prospective cohort studies. Study
populations were to include ≥ 100 patients; age > 18 years;
diagnosis of moderate-to-severe psoriasis; treatment with aci-
tretin, ciclosporin, FAE or methotrexate; and follow-up time ≥
3 months. A recent systematic review of observational studies
in patients with psoriasis specified a minimum of 100 patients
prescribed each therapy to increase statistical power, therefore
the same requirement was applied in this review.11
Disease severity was ascertained through the inclusion criteria
for each study (e.g. patients with moderate-to-severe psoriasis)
or baseline measures of severity indicating moderate-to-severe
diagnoses, namely Psoriasis Area and Severity Index (PASI) >10,
involved body surface area > 10% and/or Dermatology Life
Quality Index (DLQI) >10. Studies where > 50% of patients
were diagnosed with psoriatic arthritis were excluded, as were
studies with pooled cohorts of patients receiving systemic thera-
pies. Case reports, RCTs and reviews were excluded.
Studies investigating persistence were included if therapy
survival probabilities, mean or median time to therapy discon-
tinuation, or the proportion of patients discontinuing therapy
within the study follow-up period were reported. Studies
investigating effectiveness were included if they reported abso-
lute change in PASI, the proportion of patients achieving PASI
50, PASI 75 or PASI 90 at ≥ 3 months (50%, 75% and 90%
reductions in PASI, respectively), improvements in Physician’s
Global Assessment (PGA) at ≥ 3 months, or the proportion of
patients discontinuing therapy due to ineffectiveness.
Study selection
After the removal of duplicate reports, titles and abstracts were
independently screened by two reviewers (S.W. and K.J.M.).
The remaining articles were read in full, with data extracted
by one reviewer (S.W.) and corroborated by the second
(K.J.M.); any articles found to meet the exclusion criteria were
removed. Reference lists of reviews were also hand searched
to identify additional publications.
Data extraction
The study characteristics extracted from each included article
were author, study design and time period, therapies studied,
number of patients per therapy, mean age, sex, mean disease
duration, the proportion of patients with psoriatic arthritis,
the mean baseline PASI and DLQI, and the proportion of
patients using combination therapy. The outcomes of interest
were extracted into a separate table along with the number of
patients at each follow-up, where possible.
Quality assessment
Two reviewers (S.W. and K.J.M.) determined the quality of
the included observational studies using the Newcastle–Ottawa
Quality Assessment Scale for Cohort Studies.12 There are nine
items included in the scale, with four items under ‘selection’
and four items under ‘outcome’ scored a maximum of one
star each, with the final item ‘comparability of cohorts’ scored
a maximum of two stars. Definitions and ratings of the biases
are provided in Appendix S2 (see Supporting Information).
This review is reported according to the Meta-analysis Of
Observational Studies in Epidemiology (MOOSE) guidelines
and is registered with PROSPERO (CRD42018099771; date 19
June 2018).
Results
The initial search produced 656 articles, with 411 remaining
after deduplication (n = 245; Fig. 1). After excluding 335 arti-
cles by title screening, 76 abstracts remained. Fifty-seven arti-
cles were excluded by abstract. Two additional articles were
found through hand searching the reference lists of the
included studies, with 21 articles read in full and assessed for
eligibility. Of the 13 articles next excluded, three studies were
removed by title or abstract due to having a cohort of < 100
patients (Appendix S3; see Supporting Information)13–15 and
10 articles were excluded for ineligibility (Appendix S4; see
Supporting Information).16–25 No studies were excluded based
on outcome definition alone. The remaining eight articles
were included in the systematic review (Table 1).
Study characteristics
Acitretin, ciclosporin and methotrexate were included in one
study,26 FAE and methotrexate in one study,27 methotrexate
in two studies28,29 and FAE in four30–33 (Table 1). Four stud-
ies were retrospective and performed at a single cen-
tre,27,28,30,31 while four were multicentre studies, three of
which were prospective26,29,33 and one retrospective.32 All
eight studies were European, with follow-up conducted from
2003 to 2014 and published in 2009–2017.
One study reported only the number of treatment cycles
instead of the number of patients (158 cycles of FAE, 174
cycles of methotrexate)27 and one study reported the baseline
characteristics for the entire cohort instead of patients register-
ing to each therapy.29 Four studies reported the proportions
of patients with no previous exposure to systemic psoriasis
therapy (incident users).26,28,31,32 Two of these four studies
investigated FAE and reported 60%31 and 81%32 of the cohort
as incident users, one study reported 67% of a methotrexate
cohort as incident users28 and one study reported the propor-
tions of incident users of acitretin, ciclosporin and methotrex-
ate as 54%, 46% and 51%, respectively.26 One article reported
the number of first-line treatment cycles for FAE (n = 116,
73%) and methotrexate (n = 70, 40%) as opposed to the
number of systemic-naive patients.27
Seven of the eight articles examined therapy discontinuation
time,26–29,31–33 with six also reporting the proportion of
patients discontinuing therapy (Table 2).26–28,31–33 All eight
studies reported effectiveness outcomes (Table 2 and Table S1;
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see Supporting Information), with six studies reporting the
proportion of patients discontinuing therapy due to ineffec-
tiveness26–28,31–33 and the other two studies reporting the
mean PASI, PASI 75 and PASI 90;29 and PASI 50, PASI 75 and
PASI 90 at 3-, 6- and 12-month time points.30
Persistence
Davila-Seijo et al. reported the probability of drug survival at 1
year as 423% for acitretin [95% confidence interval (CI)
369–476], 233% for ciclosporin (95% CI 190–278) and
503% for methotrexate (95% CI 463–542), with median
discontinuation times of 072, 045 and 101 years, respec-
tively (Table 2).26 Over the 5-year study period 34%, 26%
and 30% of patients discontinuing acitretin, ciclosporin and
methotrexate, respectively, did so for ineffectiveness
(Table S1), with 14%, 18% and 17% discontinuing for
adverse events.26
One study reported mean treatment durations of 356
months (95% CI 278–435) and 223 months (95% CI 176–
271) for FAE and methotrexate, respectively; the most com-
mon reasons for discontinuation during the 5-year study
Table 1 Newcastle characteristics of the studies included in the systematic review
Study Design Baseline Characteristics*
Arnold et al.26 Retrospective, single centre,
2003–2014
FAE: n = 158 treatment
courses
Age (SD): 504 years
(152)
Females: 339%
PASI (SD): 130 (78)
116 courses first-line
systemic therapy
Methotrexate: n = 174 treatment courses
Age (SD): 517 years (126)
Females: 425%
PASI (SD): 123 (70)
70 courses first-line systemic therapy
Cabello et al.27 Retrospective, single centre,
2007–2014
Methotrexate: n = 218
Age (SD): 458 years (15)
PASI (SD): 74 (67); DLQI (SD): 82 (51)
Systemic na€ıve: 67%
Combination therapies: 87% monotherapy,
13% receiving another systemic treatment
Davila-Seijo et al.25 Prospective, multicentre
(BIOBADADERM),
2008-2013,
(Median follow-up (range):
33 years (0-51))
Acitretin=n = 340
Age (SD): 55 years (15)
Females: 31%
PASI (SD): 9 (6)
Systemic na€ıve: 54%
Combination therapies:
2 cycles MTX, 3 cycles CsA
Ciclosporin=n = 356
Age (SD): 43 years (14)
Females: 49%
PASI (SD): 13 (9)
Systemic na€ıve: 46%
Combination therapies:
5 cycles MTX, 5 cycles ACI
Methotrexate: n = 638
Age (SD): 49 years (15)
Females: 45%
PASI (SD): 9 (6)
Systemic na€ıve: 51
Combination therapies:
11 cycles CsA, 8 cycles ACI
Inzinger et al.29 Retrospective,
single centre (PsoRA),
2004-2011
FAE: n = 200
Age (SD): 404 years (133)
PASI (SD): 116 (5)
Ismail et al.30 Retrospective,
single centre, 2003-2012
FAE: n = 249
Age (range): 445 years (17-82); females: 36%
PASI (range): 92 (0-222); DLQI (range): 134 (0-27)
Systemic na€ıve: 60%
Maul et al.28 Prospective,
multicentre (SDNTT),
2011-2014
Methotrexate†: n = 119 (total 158)
Age: 471 years; females: 316%
PASI (SD, range): 92 (61: 00-324); DLQI (SD, range):
107 (66: 00-270)
Reich et al.31 Retrospective,
multicentre (FUTURE),
dates not provided
FAE: n = 984
Age (SD, range): 505 years (1318, 15-105); females: 418%
Systemic na€ıve: 806%
Walker et al.32 Prospective,
multicentre (74 private
practices
and 4 hospitals in Germany)
FAE: n = 249
Age (range): 497 years (18-89); females: 44%
PASI: 1683; DLQI: 995
Combination therapies: 354% concomitant medication
Acitretin (ACI): ciclosporin (CsA): fumaric acid esters (FAE): methotrexate (MTX): psoralen ultraviolet A (PUVA): ultraviolet B (UVB): stan-
dard deviation (SD): psoriatic arthritis (PsA): Psoriasis Area and Severity Index (PASI): Physician Global Assessment (PGA): Dermatology Life
Quality Index (DLQI): Psoriasis Register Austria (PsoRA): Swiss Dermatology Network for Targeted Therapies (SDNTT): Dermatology Clinical
Effectiveness Research Network (DCERN) *Mean age, disease duration, PASI and DLQI values presented with range. †Baseline characteristics
provided only for total systemic cohort including FAE (27), CsA (6), and retinoids (6)
© 2019 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
British Journal of Dermatology (2019)
4 Persistence and effectiveness of systemic therapies for psoriasis, K.J. Mason et al.
period were adverse events and ineffectiveness (42% and
21%, respectively, for FAE; 22% and 21% for methotrexate;
Table S1).27 Two studies reported the mean duration of FAE
therapy as 28 months (range 1 week to 106 months)31 and
50 months (no range),32 with another two studies reporting
mean durations of methotrexate therapy of 172  136
months28 and 77 months (range 0–36;29 Table S1). The most
common reasons for discontinuation among studies reporting
the proportion of patients discontinuing FAE were adverse
events (46% over 4 years;31 43% over 1 year)33 and ineffec-
tiveness (22% over 36 months),32 and adverse events for
methotrexate (22% over 48 weeks;28 Table S1).
Effectiveness
Mean PASI values at baseline and 12 months were reported in
two studies; Walker et al. reported mean PASI of 168 and 56,
respectively, for patients receiving FAE,33 while Maul et al.
reported mean PASI of 114 and 22, respectively, for patients
receiving methotrexate (Table 2).29 Two studies reported that
76% of FAE patients on therapy at 1 year achieved PASI 7530
and PGA of markedly improved or clear.32 Two studies
reported that 53%28 and 59%29 of patients on methotrexate
remaining on therapy at 1 year achieved PASI 75 (Table 2).
Two studies also reported discontinuations due to ineffective-
ness for FAE (40% over 4 years;31 11% over 1 year)33 and
one for methotrexate (21% over 48 weeks;28 Table S1). Effec-
tiveness outcomes with PASI or PGA were not reported for
ciclosporin or acitretin.
Quality assessment
Two studies were rated as ‘high quality’26,27 (scored > 7),
with the remaining six studies rated ‘medium quality’28–33
(scored 4–6). None of the six studies rated as ‘medium qual-
ity’ adjusted for age, sex or any other confounding factors in
their persistence or effectiveness analyses.28–33 A meta-analysis
was not conducted due to the diverse study designs, outcome
definitions and analytical approaches used (Table 3).
Discussion
This systematic review found that in the treatment of moder-
ate-to-severe plaque psoriasis the probability of drug survival
at 1 year was 23% for ciclosporin, 42% for acitretin and
50% for methotrexate.26 Discontinuations due to adverse
events (42% FAE and 22% methotrexate,27 46% FAE,31 43%
FAE,33 22% methotrexate)28 were more common for FAE
than for methotrexate. There were mixed results for discon-
tinuations due to ineffectiveness (44% acitretin, 21% ciclos-
porin and 33% methotrexate;26 22% FAE).32 No studies
reported effectiveness outcomes for acitretin or ciclosporin.
The persistence and effectiveness of FAE and methotrexate
were better characterized, but mean discontinuation times
ranged from 28 to 50 months (FAE)27,31,32 and 77 to 223
months (methotrexate).26–29 Proportions of patients achieving
PASI 75 at 12 months were reported for FAE (76%)30 and
methotrexate (53%28 and 59%),29 with 76% of patients on
FAE achieving a PGA of markedly improved or clear at 12
months.32
A significant limitation to the current literature investigating
the persistence of systemic therapy is the lack of survival anal-
yses. Survival analyses are essential when using observational
methods to explore drug persistence, because without them,
differing lengths of follow-up will not be accounted for. NICE
recommends that ciclosporin use should not exceed 1 year
unless patients have severe and/or unstable disease and biolo-
gic therapy is contraindicated. As ciclosporin is usually pre-
scribed for short durations, the lack of long-term persistence
should not be viewed as a proxy for poor safety or ineffective-
ness of this therapy.3 Of the eight studies identified, one con-
ducted a survival analysis on the time to drug discontinuation
for patients using each systemic therapy.26 Three additional
studies also conducted survival analyses; however, one pooled
all systemic therapies into a systemic cohort,29 the second
reported treatment courses rather than patients,27 and the
third study did not provide the definition for discontinuation
Fig 1. Flowchart of the article selection. Studies were identified by
searching Embase, MEDLINE, PubMed and the Cochrane Library then
filtered according to title, abstract and eligibility. Additional articles
were identified by manually searching reference lists.
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used in the survival analysis,28 making the results difficult to
interpret.
A further limitation to the studies exploring therapy persis-
tence is the inconsistent definition of drug discontinuation. Of
the seven studies reporting therapy persistence, four did not
provide any definition of drug discontinuation.29,31–33 One
study defined discontinuation as ‘a suspension of medication’
due to a range of possibilities, however, it did not specify
what a ‘suspension’ was or a time frame.28 Two studies pro-
vided a sufficient definition of a discontinuation, providing a
time frame for how long patients were not using therapy.26,27
Due to the lack of, and difference in, a definition of discontin-
uation, it is difficult to ascertain whether short-term breaks in
therapy have been accounted for. Definitions of drug
discontinuation and time frames are particularly important
when interpreting ciclosporin survival, as this is generally
given for short periods of time.
Many of the included studies lack complete reporting and
analysis of baseline characteristics. Evidence shows there are
differences in the prescribing patterns of psoriasis therapies
for different patients,34 while the definition of moderate-to-
severe psoriasis remains inconsistent, resulting in a range of
baseline severities used between countries and healthcare sys-
tems. It would therefore be beneficial to assess the baseline
characteristics of the therapy cohorts separately to identify dif-
ferences between them. One study pooled the characteristics
of the different therapy cohorts29 and five studies did not
report three or more of the baseline measurements
Table 2 Summary of evidence
Drug (reference) Number of Patients Results
Persistence
Probability of drug survival at 12 months
ACI25 340 423% (95% CI 369%-476%)
CsA25 356 233% (95% CI 190%-278%)
MTX25 638 503% (95% CI 463%–542%)
Therapy discontinuation time
ACI25 340 Median; 072 years (no range)
CsA25 356 Median; 045 years (no range)
FAE26 158* Mean; 356 months (95% CI 278-435)
FAE30 249 Mean; 28 months (1 week-106 months)
FAE31 984 Mean; 50 months (no range)
MTX25 638 Median; 101 years (no range)
MTX26 174* Mean; 223 months (95% CI 176–271)
MTX27 218 Mean; 172 months (SD; 136)
MTX28 119 Mean; 77 months (range 0–36)
Effectiveness
Mean PASI Values
FAE32 Baseline: 249 1683
12 months: 145 561
MTX28 Baseline: 119 114
3 months: 80 33
6 months: 55 22
12 months: 28 22
Proportion of patients achieving improvements in disease severity: n (%)
FAE29 3 months: 115 PASI50: 87 (76%); PASI75: 54 (47%); PASI90: 10 (9%)
6 months: 73
12 months: 41 PASI50: 60 (82%); PASI75: 46 (63%); PASI90: 20 (27%)
PASI50: 37 (90%); PASI75: 31 (76%); PASI90: 14 (34%)
FAE (PGA markedly
improved/clear)31
3 months: 953 294 (308%)
6 months: 941 630 (670%)
12 months: 936 713 (762%)
24 months: 901 701 (778%)
36 months: 566 465 (821%)
>36 months: 566 473 (836%)
MTX27 Not provided for separate
time points
PASI75: Week 12: 325%; Week 16: 344%; Week 24: 447%; Week 36:
500%; Week 48: 528%
MTX28 3 months: 81 PASI75: 30 (37%); PASI90: 11 (136%)
6 months: 56 PASI75: 30 (536%); PASI90: 16 (286%)
12 months: 29 PASI75: 17 (586%); PASI90: 13 (448%)
Acitretin (ACI); ciclosporin (CsA); fumaric acid esters (FAE); methotrexate (MTX); 95% CI (95% confidence interval); Psoriasis Area and
Severity Index (PASI); Physician Global Assessment (PGA). *Treatment courses. †Number discontinuing therapy.
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listed.27,28,30,32,33 This lack of detail makes the quality assess-
ment both within and between studies more difficult.
There is little acknowledgment of prevalent-user bias
throughout the current literature. A prevalent user can be
defined as a patient who previously used the therapy of inter-
est before the start of the study follow-up, then restarted the
same therapy during the study period.35 The inclusion of such
patients within an analysis can bias results as they may have
been exposed to a specific therapy previously and could be
prescribed this again due to a previous positive response, or
they could be exposed to a new therapy if their initial treat-
ment failed. One study reported the proportion of incident
users within the entire cohort and one reported the propor-
tion of treatment courses that were first line,27 while only
four studies provided the proportions of incident users for
individual therapies.26,28,31,32 It would be beneficial to con-
duct sensitivity analyses with and without prevalent users to
identify whether prevalent-user bias is present.
The discontinuation of previous therapy could also influ-
ence the disease severity recorded prior to initiating a new
one, particularly if there are minimal washout periods or
overlaps between them. By reporting both the aggregate esti-
mates and estimates stratified by therapy, we can understand
better whether previous therapy exposure affects drug persis-
tence or effectiveness. Another factor that influences the per-
sistence or effectiveness of therapies is medication adherence.
Patients with psoriasis registering to BADBIR on acitretin,
ciclosporin, FAE or methotrexate were almost twice as likely
to be nonadherent (292%) as patients receiving etanercept or
adalimumab (164%, P < 0001).36 Medication adherence
should be assessed when investigating treatment response, par-
ticularly whether nonadherence is intentional (e.g. medication
perceived to be ineffective) or unintentional (e.g. lower per-
sistence related to habit strength).
The results of this review reflect the contemporary evidence
for the persistence and effectiveness of systemic psoriasis ther-
apies within the real-world environment. Since performing
our database search, one conference abstract has been
published as a manuscript. The authors performed a single-
centre, retrospective study of 626 patients with psoriasis
receiving FAE monotherapy, and demonstrated a median dura-
tion of therapy of 17 years, with 188 patients (30%) discon-
tinuing therapy.37 The introduction of biologic and small-
molecule therapies in the past decade is likely to have influ-
enced the persistence of acitretin, ciclosporin, FAE and
methotrexate in clinical practice, which is yet to be addressed
in the literature. Future analyses should stratify by year of ini-
tiation to account for changes in the prescribing environment
and thus the persistence of these therapies over time.
The complexity of studying persistence and effectiveness of
therapy in clinical practice is highlighted by the varying
results, study cohorts and methods of reporting. The inconsis-
tent methods of reporting prevented a meta-analysis from
being conducted. There was also the potential to introduce
bias via the outcome definition specified in the protocol for
this systematic review. Although no studies were excluded
based on outcome definition alone (Appendix S4; see Support-
ing Information), future reviews of this topic should consider
the use of a more robust definition to minimize the risk of
excluding a study that used a different but relevant outcome
definition.
In conclusion, this systematic review highlights how evi-
dence for the persistence and effectiveness of systemic thera-
pies for psoriasis in clinical practice is lacking. There are few
studies exploring acitretin or ciclosporin, and those that have
examined FAE or methotrexate are difficult to compare due to
incomplete reporting of baseline characteristics, insufficient
survival analyses and differing definitions of drug discontinua-
tion. There is therefore a need for good-quality observational
research, with an additional need for uniform methods of
analysis and reporting to allow for meta-analyses.
Acknowledgments
The authors acknowledge the substantial contribution of the
BADBIR team to the administration of the project. BADBIR
Table 3 Newcastle–Ottawa Quality Assessment Scale for Cohort Studies
Study Arnold27 Cabello Zurita28 Davila-Seijo26 Inzinger30 Ismail31 Maul29 Reich32 Walker33
Selection (maximum one star per item)
Representativeness of exposed cohort (b) * (b) * (a) * (b) * (b) * (a) * (a) * (a) *
Selection of nonexposed cohort N/A N/A N/A N/A N/A N/A N/A N/A
Ascertainment of exposure (a) * (a) * (a) * (a) * (a) * (b) * (b) * (b) *
Outcome not present at baseline (a) * (a) * (a) * (a) * (a) * (a) * (a) * (a) *
Comparability of cohorts (maximum two stars)
Matching (a, b) ** 0 (a) * 0 0 0 0 0
Outcome (maximum one star per item)
Assessment of outcome (b) * (b) * (b) * (b) * (b) * (b) * (b) * (b) *
Length of follow-up (a) * (a) * (a) * (a) * (a) * (a) * (a) * (a) *
Adequacy of follow-up (d) (d) (b) * (b) * (b) * (a) * (a) * (c)
Total score 7 5 7 6 6 6 6 5
N/A, not applicable. See Appendix S2 in the Supporting Information for descriptions of the letter codes.
© 2019 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
British Journal of Dermatology (2019)
Persistence and effectiveness of systemic therapies for psoriasis, K.J. Mason et al. 7
acknowledges the support of the NIHR through the clinical
research networks and its contribution in facilitating recruit-
ment into the registry. The views and opinions expressed
herein are those of the authors and do not necessarily reflect
those of the BADBIR, NIHR, NHS or Department of Health.
The authors are grateful to the members of the Data Monitor-
ing Committee: Dr Robert Chalmers, Professor Carsten Flohr
(chair), David Prieto-Merino and Dr Richard Weller; and the
BADBIR Steering Committee (in alphabetical order): Professor
Jonathan Barker, Ms Marilyn Benham (CEO of BAD), Professor
David Burden (chair), Mr Ian Evans, Professor Christopher
Griffiths, Dr Sagair Hussain, Professor Brian Kirby, Ms Linda
Lawson, Dr Kayleigh Mason, Dr Kathleen McElhone, Dr Ruth
Murphy, Professor Anthony Ormerod, Dr Caroline Owen, Pro-
fessor Nick Reynolds, Professor Catherine Smith and Professor
Richard Warren. Finally, we acknowledge the enthusiastic col-
laboration of all of the dermatologists and specialist nurses in
the U.K. and the Republic of Ireland who provided the data.
The principal investigators at the participating sites at the time
of data cut-off are listed at http://www.badbir.org.
References
1 Dubertret L, Mrowietz U, Ranki A et al. European patient perspec-
tives on the impact of psoriasis: the EUROPSO patient membership
survey. Br J Dermatol 2006; 155:729–36.
2 Strober BE, Siu K, Menon K. Conventional systemic agents for pso-
riasis. A systematic review. J Rheumatol 2006; 33:1442–6.
3 National Institute for Health and Care Excellence. Psoriasis: assess-
ment and management. Clinical guideline CG153. Available at:
https://www.nice.org.uk/guidance/cg153 (last accessed 14
February 2019).
4 Mason KJ, Barker J, Smith CH et al. Comparison of drug discontinua-
tion, effectiveness, and safety between clinical trial eligible and ineli-
gible patients in BADBIR. JAMA Dermatol 2018; 154:581–8.
5 Garcia-Doval I, Carretero G, Vanaclocha F et al. Risk of serious
adverse events associated with biologic and nonbiologic psoriasis
systemic therapy: patients ineligible versus eligible for randomized
controlled trials. Arch Dermatol 2012; 148:463–70.
6 Cramer JA, Roy A, Burrell A et al. Medication compliance and
persistence: terminology and definitions. Value Health 2008; 11:44–7.
7 Singal AG, Higgins PD, Waljee AK. A primer on effectiveness and
efficacy trials. Clin Transl Gastroenterol 2014; 5:e45.
8 Barbosa CD, Balp MM, Kulich K et al. A literature review to explore
the link between treatment satisfaction and adherence, compliance,
and persistence. Patient Prefer Adherence 2012; 6:39–48.
9 Freeman K, Marum M, Bottomley JM et al. A psoriasis-specific
model to support decision making in practice U.K. – experience.
Curr Med Res Opin 2011; 27:205–23.
10 Burden AD, Warren RB, Kleyn CE et al. The British Association of
Dermatologists’ Biologic Interventions Register (BADBIR): design,
methodology and objectives. Br J Dermatol 2012; 166:545–54.
11 Langham S, Langham J, Goertz HP, Ratcliffe M. Large-scale,
prospective, observational studies in patients with psoriasis and
psoriatic arthritis: a systematic and critical review. BMC Med Res
Methodol 2011; 11:32.
12 Wells GA, Shea B, O’Connell D et al. The Newcastle–Ottawa Scale
(NOS) for assessing the quality of nonrandomised studies in meta-
analyses. Available at: http://www.ohri.ca/programs/clinical_epi
demiology/oxford.asp (last accessed 14 February 2019).
13 Wain EM, Darling MI, Pleass RD et al. Treatment of severe, recalci-
trant, chronic plaque psoriasis with fumaric acid esters: a prospec-
tive study. Br J Dermatol 2010; 162:427–34.
14 Borghi A, Corazza M, Bertoldi AM et al. Low-dose acitretin in treat-
ment of plaque-type psoriasis: descriptive study of efficacy and
safety. Acta Derm Venereol 2015; 95:332–6.
15 Borghi A, Corazza M, Mantovani L et al. Prolonged cyclosporine
treatment of severe or recalcitrant psoriasis: descriptive study in a
series of 20 patients. Int J Dermatol 2012; 51:1512–16.
16 Calara PS, Norlin JM, Althin R et al. Healthcare provider type and
switch to biologics in psoriasis: evidence from real-world practice.
BioDrugs 2016; 30:145–51.
17 Christophers E, Segaert S, Milligan G et al. Clinical improvement
and satisfaction with biologic therapy in patients with severe pla-
que psoriasis: results of a European cross-sectional observational
study. J Dermatolog Treat 2013; 24:193–8.
18 Gelfand JM, Wan J, Callis Duffin K et al. Comparative effectiveness
of commonly used systemic treatments or phototherapy for mod-
erate to severe plaque psoriasis in the clinical practice setting. Arch
Dermatol 2012; 148:487–94.
19 Jungo P, Maul JT, Djamei V et al. Superiority in quality of life
improvement of biologics over conventional systemic drugs in a
Swiss real-life psoriasis registry. Dermatology 2017; 232:655–63.
20 Norlin JM, Carlsson KS, Persson U, Schmitt-Egenolf M. Register-
based evaluation of relative effectiveness of new therapies: biolog-
ics versus conventional agents in treatment of psoriasis in Sweden.
BioDrugs 2015; 29:389–98.
21 Norlin JM, Steen Carlsson K, Persson U, Schmitt-Egenolf M. Switch
to biological agent in psoriasis significantly improved clinical and
patient-reported outcomes in real-world practice. Dermatology 2012;
225:326–32.
22 Lambert J, Ghislain PD, Cauwe B, Van den Enden M. Treatment pat-
terns in moderate-to-severe plaque psoriasis: results from a Belgian
cross-sectional study (DISCOVER). J Dermatolog Treat 2017; 28:394–400.
23 Yeung H, Wan J, Van Voorhees AS et al. Patient-reported reasons
for the discontinuation of commonly used treatments for moderate
to severe psoriasis. J Am Acad Dermatol 2013; 68:64–72.
24 Shear N, Dobson-Belaire W, Tey G et al. Psoriasis treatment pro-
gression and biologic utilization: a Canadian retrospective study. J
Am Acad Dermatol 2015; 72 (5 Suppl. 11):AB246.
25 Svedbom A, Dalen J, Mamolo C et al. Treatment patterns with topi-
cals, traditional systemics and biologics in psoriasis – a Swedish
database analysis. J Eur Acad Dermatol Venereol 2015; 29:215–23.
26 Davila-Seijo P, Dauden E, Carretero G et al. Survival of classic and
biological systemic drugs in psoriasis: results of the BIOBADA-
DERM registry and critical analysis. J Eur Acad Dermatol Venereol 2016;
30:1942–50.
27 Arnold T, Schaarschmidt M-L, Herr R et al. Drug survival rates and
reasons for drug discontinuation in psoriasis. J Dtsch Dermatol Ges
2016; 14:1089–99.
28 Cabello Zurita C, Grau Perez M, Hernandez Fernandez CP et al.
Effectiveness and safety of methotrexate in psoriasis: an eight-year
experience with 218 patients. J Dermatolog Treat 2017; 28:401–5.
29 Maul JT, Djamei V, Kolios AGA et al. Efficacy and survival of sys-
temic psoriasis treatments: an analysis of the Swiss registry SDNTT.
Dermatology 2017; 232:640–7.
30 Inzinger M, Weger W, Heschl B et al. Methotrexate vs. fumaric
acid esters in moderate-to-severe chronic plaque psoriasis: data
registry report on the efficacy under daily life conditions. J Eur Acad
Dermatol Venereol 2013; 27:861–6.
31 Ismail N, Collins P, Rogers S et al. Drug survival of fumaric acid
esters for psoriasis: a retrospective study. Br J Dermatol 2014;
171:397–402.
© 2019 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
British Journal of Dermatology (2019)
8 Persistence and effectiveness of systemic therapies for psoriasis, K.J. Mason et al.
32 Reich K, Thaci D, Mrowietz U et al. Efficacy and safety of fumaric
acid esters in the long-term treatment of psoriasis – a retrospective
study (FUTURE). J Dtsch Dermatol Ges 2009; 7:603–11.
33 Walker F, Adamczyk A, Kellerer C et al. Fumaderm in daily practice
for psoriasis: dosing, efficacy and quality of life. Br J Dermatol
2014; 171:1197–205.
34 Davison NJ, Warren RB, Mason KJ et al. Identification of factors
that may influence the selection of first-line biological therapy for
people with psoriasis: a prospective, multicentre cohort study. Br J
Dermatol 2017; 177:828–36.
35 Ray WA. Evaluating medication effects outside of clinical trials:
new-user designs. Am J Epidemiol 2003; 158:915–20.
36 Thorneloe RJ, Griffiths CEM, Emsley R et al. Intentional and unin-
tentional medication non-adherence in psoriasis: the role of
patients’ medication beliefs and habit strength. J Invest Dermatol
2018; 138:785–94.
37 Dickel H, Bruckner T, Altmeyer P. Long-term real-life safety profile
and effectiveness of fumaric acid esters in psoriasis patients: a sin-
gle-centre, retrospective, observational study. J Eur Acad Dermatol
Venereol 2018; 32:1710–27.
Appendix
Funding sources
The British Association of Dermatologists Biologics and
Immunomodulators Register (BADBIR) is coordinated by the
University of Manchester and funded by the British Associa-
tion of Dermatologists (BAD). The BAD receives income from
AbbVie, Almirall, Celgene, Eli Lilly, Hexal AG, Janssen Cilag,
Novartis, Pfizer and Samsung Bioepis for providing pharma-
covigilance services. This income finances a separate contract
between the BAD and the University of Manchester, who
coordinate BADBIR. All decisions concerning analysis, inter-
pretation and publication are made independently of any
industrial contribution. N.J.R.’s research and laboratory are
funded in part by the Newcastle National Institute for Health
Research (NIHR) Biomedical Research Centre (BRC), the New-
castle NIHR Medtech and In Vitro Diagnostic Co-operative and
the Newcastle MRC/EPSRC Molecular Pathology Node. C.H.S.
receives funding from the NIHR Biomedical Research Centre
at King’s College London/Guy’s and St Thomas’ NHS Founda-
tion Trust. C.E.M.G. and R.B.W.’s research is in part funded
by the Manchester NIHR BRC. C.E.M.G. is an NIHR Senior
Investigator.
Conflicts of interest
K.J.M. has received honoraria from Eli Lilly and Janssen. K.M.
has received honoraria from Eli Lilly. D.M.A. has received
research grants from AbbVie, Almirall, Celgene, Eli Lilly,
Novartis, UCB and the LEO Foundation. C.E.K. has acted as a
consultant and/or speaker for and/or received research grants
from AbbVie, Almirall, Celgene, Eli Lilly, Pfizer, LEO Pharma,
Novartis, Janssen Cilag, Medac and UCB Pharma. N.J.R. reports
research grants from AstraZeneca and Stiefel GSK; and other
income to Newcastle University from Almirall, Amgen, Jans-
sen and Novartis for lectures or attendance at advisory boards.
C.H.S. has received research funding from AbbVie, GSK, Pfi-
zer, Novartis, Regeneron and Roche. R.B.W. has acted as a
consultant and/or speaker for and/or received research grants
from AbbVie, Amgen, Almirall, Celgene, Eli Lilly, Pfizer, LEO
Pharma, Novartis, Janssen Cilag, Medac, UCB Pharma and
Xenoport. C.E.M.G. has received honoraria and/or research
grants from AbbVie, Almirall, Amgen, Bristol-Myers Squibb,
Celgene, Galderma, LEO Pharma, Eli Lilly, GSK-Stiefel, Janssen
Cilag, MSD, Novartis, Pfizer, Sandoz and UCB Pharma. S.W.,
Z.Z.N.Y., Z.K.J.L., C.M.O. and N.W. declare no conflicts of
interest.
Supporting Information
Additional Supporting Information may be found in the online
version of this article at the publisher’s website:
Table S1 The characteristics of the studies included in the
systematic review.
Appendix S1 Study protocol: persistence and effectiveness
of systemic psoriasis therapies.
Appendix S2 Definitions of the biases assessed within the
included studies.
Appendix S3 Studies excluded due to including < 100
patients.
Appendix S4 Studies excluded due to ineligibility.
© 2019 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
British Journal of Dermatology (2019)
Persistence and effectiveness of systemic therapies for psoriasis, K.J. Mason et al. 9
